Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Causes of hOCT1‐Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor‐Selective Gene Therapy

11 Apr 2019

Abstract excerpt

Although the multi-tyrosine kinase inhibitor sorafenib is useful in the treatment of several cancers, cholangiocarcinoma (CCA) is refractory to this drug. Among other mechanisms of chemoresistance, impaired uptake through human organic cation transporter type 1 (hOCT1) (gene SLC22A1) has been suggested. Here we have investigated the events accounting for this phenotypic characteristic and have evaluated the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cholangiocarcinoma and Gallbladder Cancer Studies
Share to Drug Transport and Resistance Mechanisms
Share to Pediatric Hepatobiliary Diseases and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30972782
DOI: 10.1002/hep.30656

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Causes of hOCT1‐Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor‐Selective Gene TherapyPMID 30972782Read ↗

Epigenetic events involved in organic cation transporter 1‐dependent impaired response of hepatocellular carcinoma to sorafenibSemantic proximity Read ↗

Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistanceSemantic proximity Read ↗

CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.Semantic proximity Read ↗

Decitabine regulates the resistance of Hep3B to sorafenib through demethylationSemantic proximity Read ↗

Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib.Semantic proximity Read ↗

Coordinated activation of DNMT3a and TET2 in cancer stem cell-like cells initiates and sustains drug resistance in hepatocellular carcinomaSemantic proximity Read ↗

Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line Resistant to GemcitabineSemantic proximity Read ↗

MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma.Semantic proximity Read ↗

DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinomaSemantic proximity Read ↗

Epigenetic regulation of DNA repair gene program by Hippo/YAP1-TET1 axis mediates sorafenib resistance in HCCSemantic proximity Read ↗

Alcohol induces sorafenib resistance in hepatocellular carcinoma: A Translational StudySemantic proximity Read ↗

Molecular cloning, functional characterization and genomic organization of four alternatively spliced isoforms of the human organic cation transporter 1 (<i>hOCT1</i>/<i>SLC22A1</i>)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.